|
- CASGEVY® (exagamglogene autotemcel) | Patient Website
CASGEVY is made specifically for each patient, using the patient’s own edited blood stem cells, and increases the production of a special type of hemoglobin called hemoglobin F (fetal hemoglobin or HbF)
- Exagamglogene autotemcel - Wikipedia
Exagamglogene autotemcel, sold under the brand name Casgevy, is a gene therapy used for the treatment of sickle cell disease [4][6] and transfusion-dependent beta thalassemia [4]
- FDA Approves First Gene Therapies to Treat Patients with Sickle Cell . . .
Casgevy, a cell-based gene therapy, is approved for the treatment of sickle cell disease in patients 12 years of age and older with recurrent vaso-occlusive crises Casgevy is the first
- Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR Cas9 . . .
Casgevy, the first FDA-approved CRISPR Cas9 gene therapy for sickle cell disease (SCD), offers a curative approach and eliminates the need for recurrent transfusions and transplants, thereby significantly enhancing the quality of life of individuals with SCD
- CASGEVY® (exagamglogene autotemcel) | Official HCP Website
Learn about CASGEVY® (exagamglogene autotemcel) on the official website for HCPs See Important Safety Information and full Prescribing Information
- Casgevy: Uses, Dosage, Side Effects, Warnings - Drugs. com
Casgevy (exagamglogene autotemcel) is a gene therapy that is given as a one-time intravenous infusion to treat adults and children aged 12 years and older with: Sickle cell disease with recurrent vaso-occlusive crises (VOCs) Transfusion-dependent β-thalassemia (TDT)
- Casgevy - European Medicines Agency (EMA)
Casgevy is a medicine used to treat blood disorders known as beta thalassaemia and sickle cell disease in patients 12 years and older For beta thalassaemia, Casgevy is used in patients who require regular blood transfusions
- CASGEVY™ - Therapies | CRISPR Therapeutics
CASGEVY™ (exagamglogene autotemcel), a CRISPR Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, is approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia
|
|
|